Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment - Archive ouverte HAL Access content directly
Journal Articles Beilstein Journal of Nanotechnology Year : 2018

Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment

(1, 2) , (2) , (2) , (1) , (3) , (2)
1
2
3

Abstract

A gold therapeutic nanoplatform with the same molecule used as reductant, coating and therapeutic agent has been developed in a one-pot, one-phase process using alendronate, a drug from the bisphosphonate family known for its antitumor effects. In addition, the core made of gold nanoparticles (NPs) brings thermal functionalities under irradiation within the first biological window (650-900 nm). The Au@alendronate nanoplatform thus provided a combined antitumor activity through drug delivery and photothermal therapy. Au@alendronate NPs inhibited in vitro the proliferation of prostate cancer cells (PC3) in a dose-dependent manner, with an IC 50 value of 100 µM. Under NIR irradiation a temperature increase was observed leading to a reduction of the IC 50 value to 1 µM, with total tumor cell death at 100 µM.
Fichier principal
Vignette du fichier
sans-titre.pdf (511.52 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-02192626 , version 1 (24-07-2019)

Identifiers

Cite

Anouchka Plan Sangnier, Romain Aufaure, Laurence Motte, Claire Wilhelm, Erwann Guénin, et al.. Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment. Beilstein Journal of Nanotechnology, 2018, 9, pp.2947-2952. ⟨10.3762/bjnano.9.273⟩. ⟨hal-02192626⟩
72 View
72 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More